secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2026-10-20T21:04:33+00:00
Accession:  0001193125-26-426828
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 3.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Surrozen closes $95.1M second tranche at $11.60/share; cash runway extended into 2029
--------------------------------------------------------------------------------

- Gross proceeds of ~$95.1M: 5,741,605 shares at $11.60, 2,456,500 pre-funded warrants at $11.5999, and Series E warrants for 4,099,052 shares at $11.54 strike.
- Second closing milestone triggered by FDA clearance of the SZN-8141 IND on October 2, 2026, under the March 24, 2025 securities purchase agreement.
- Post-closing capitalization: ~17.8M common shares outstanding, 3.8M issuable on pre-funded warrants, 9.1M on common warrants (mostly $11.54 strike, expiring 2029-2031).
- Cash, equivalents and marketable securities expected to fund runway into 2029, including the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143.
- Must file a resale S-3 within 30 days of closing and seek effectiveness within 90 days (120 if full SEC review).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/0001193125-26-426828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/srzn-20261020.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-426828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer